Related Experiment Videos
[Development of toxin targeting to VEGF-KDR]
Jie Wu1, Hui-peng Chen, Hong-bin Zhang
1Medical Research Department, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou 510010, China.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|April 3, 2004
Summary
A novel fusion protein, P5-StxA, targets vascular endothelial growth factor receptor II (VEGF-II/KDR) with high affinity. This engineered toxin selectively inhibits angiogenesis, offering a potential targeted therapy for diseases involving abnormal blood vessel growth.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Context:
- Vascular endothelial growth factor receptor II (VEGF-II/KDR) is crucial for angiogenesis.
- Targeting VEGF-II/KDR offers a strategy for anti-angiogenic therapy.
- Developing targeted toxins can enhance therapeutic efficacy and reduce side effects.
Purpose:
- To develop a targeted toxin by fusing a KDR-binding peptide (P5) with Shiga toxin subunit A (StxA).
- To screen and identify high-affinity KDR-binding peptides using phage display.
- To evaluate the efficacy and specificity of the resulting fusion protein (P5-StxA).
Summary:
- A high-affinity KDR-binding peptide, P5, was identified and fused to Shiga toxin subunit A (StxA) to create P5-StxA.
- The fusion protein P5-StxA demonstrated specific binding to KDR and retained the cytotoxic activity of StxA.
- In a chick chorioallantoic membrane model, P5-StxA selectively inhibited VEGF-induced angiogenesis.
Impact:
- P5-StxA shows potential as a targeted therapeutic agent for angiogenesis-dependent diseases.
- The study validates the use of peptide-toxin fusion as a strategy for targeted drug delivery.
- This approach may lead to novel treatments for cancers and other conditions characterized by aberrant blood vessel formation.